Ivermectin for COVID-19: From Pandemic Controversy to Definitive Futility in the REMAP-CAP and Global Randomized Trials

Highlights

• The REMAP-CAP trial found no clinical benefit for ivermectin in improving organ support-free days or hospital survival in critically or non-critically ill patients.
• Large-scale meta-analyses involving over 23,000 participants confirm that ivermectin does not reduce all-cause mortality in either hospitalized or outpatient settings.
• Evidence from major platform trials like PRINCIPLE and ACTIV-6 demonstrates that ivermectin is unlikely to provide clinically meaningful improvements in recovery time or prevent hospitalization.
• International clinical guidelines now strongly discourage ivermectin use, citing a lack of high-quality evidence despite its widespread political and public distribution early in the pandemic.

Background